Gastrointestinal sistem kanamalarında yeni kuşak oral antikoagülan ilaçların yeri

Yıl 2016, Cilt: 24 Sayı: 2, 29 - 35, 31.08.2016

Sema Kaymaz Tahra Yaşar Çolak Ebubekir Şenateş , Miraç Vural Keskinler Hakan Dursun İlyas Tuncer Aytekin Oğuz

https://doi.org/10.17940/endoskopi.328228

Öz

Giriş ve Amaç: Yeni oral antikoagülanların kullanıma girdiği bu ilk yıllarda herhangi bir antikoagülan ve/veya antiagregan kullanmakta iken gastrointestinal kanama sebebiyle hastanemize başvuran ve gastrointestinal sistem kanaması tanısıyla yatırılan hastalarda gastrointestinal sistem kanama sebepleri arasında yeni oral antikoagülanların yerini belirlemek ve ilaç grupları ile kanama ciddiyeti ve klinik tablo arasındaki ilişkilerin değerlendirilmesidir. Gereç ve Yöntem: Bu retrospektif çalışmaya antikoagülan ve/veya antiagregan kullanmakta iken gastrointestinal sistem kanama nedeniyle kliniğimize yatan toplam 178 hasta (ortalama yaş: 70±14 yaş) alındı. Hastalar yalnız antiagregan kullanan (n=124), yalnız antikoagülan kullanan (n=43) ve kombine ilaç kullanan (n=11) olarak üç ana gruba ayrıldı. Gruplar demografik veriler, biyokimyasal değerleri, 24 saatlik takip dilimlerinde maksimum hemoglobin düşüşleri, kan transfüzyonu miktarı ve mortalite oranlarına göre karşılaştırıldı. Bulgular: Hastaların ilaç kullanımına göre dağılımı; %70’inin antiagregan ilaç, %20’sinin varfarin, %4’ünün yeni oral antikoagülan, %6’sının kombine ilaç kullanımı şeklinde idi. Antiagregan ilaç grubunda %75 oranında aspirin kullanımı vardı. Antikoagülana bağlı kanamalarda ise varfarin %84, yeni oral antikoagülan ilaçlar %16 oranında tespit edildi. Antiagregan, antikoagülan ve kombine ilaç kullanım grupları arasında mortalite oranı (p=0.50), transfüzyon miktarı (p=0.72) ve maksimum hemoglobin düşüşleri (p=0.39) arasında fark saptanmadı. Yeni oral antikoagülanlar ile varfarin arasında morbidite ve mortalite oranlarında farklılık saptanmadı. Sonuç: Sonuç olarak yeni oral antikoagülanlar, antikoagülan ve/veya antiagregan kullanımı sonrası gastrointestinal kanama nedenleri arasında yer almaya başlamıştır. Varfarin ve yeni oral antikoagülanlarla ilişkili kanamaya bağlı morbidite ve mortalite oranları arasında anlamlı fark saptanmamıştır ancak bu ilaçların önümüzdeki yıllarda daha yaygın kullanımı ile gastrointestinal kanama etiyolojisindeki yerinin daha da artabileceği göz önüne alınmalıdır

Anahtar Kelimeler

Antikoagülan, antiagregan, gastrointestinal kanama, yeni kuşak oral antikoagülan

The implication of new oral anticoagulant agents in gastrointestinal bleeding

Öz

Background and Aims: This study was designed to (i) address the position of new oral anticoagulants in the etiology of bleeding in patients admitted to our hospital for gastrointestinal bleeding while using any anticoagulant and/ or any antiaggregant drug and (ii) assess the relationships between the drug groups and severity of bleeding and the clinical picture in the first years of new oral anticoagulant use. Material and Methods: A total of 178 patients (mean age: 70±14 years) who were admitted to our clinic for gastrointestinal bleeding while using an anticoagulant and/or antiaggregant agent were recruited retrospectively. Patients were divided into the following three primary categories: patients using antiaggregant drugs (n=124), anticoagulant drugs (n=43), and both (n=11). The groups were compared according to their demographic data, biochemical parameters, 24-h follow-up period, maximum decrease in hemoglobin levels, amount of blood transfused, and mortality rates. Results: A total of 70% of the patients were taking antiaggregant drugs, 20% were using warfarin, 4% were taking new oral anticoagulants, and 6% of them were taking a combination of anticoagulants and antiaggregants. A total of 75% of the patients were using aspirin, 84% were taking warfarin, and 16% were taking new oral anticoagulants. There was no difference between the groups in terms of mortality rate (p=0.50), transfusion amount (p=0.72), and maximum hemoglobin decrease (p=0.39). There was also no difference in morbidity and mortality rates between patients taking new oral anticoagulants and those taking warfarin. Conclusion: Use of new oral anticoagulants has been listed as a cause for gastrointestinal bleeding. Although there was no difference between warfarin and new oral anticoagulant treatment with regard to mortality and morbidity rates, with the increasing use of these drugs in the forthcoming years, augmentation of their position in gastrointestinal bleeding etiology should be considered.

Anahtar Kelimeler

Anticoagulant, antiaggregant, gastrointestinal bleeding, new oral anticoagulants

Kaynakça

• REFERENCES 1. Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: Relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002;97:2540-9. 2. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease Review and Assessment: Pathophysiology/Diagnosis/Management, ninth edition 2010:285-322. 3. Morris AI. Upper Gastrointestinal Hemorrhage. Medicine International Gastroenterology. Oxford, Great Britain OX1 1B L. 1986;1013-7. 4. Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006;55:1731-8. 5. Pipilis A, Makrygiannis S, Chrısanthopoulou E, et al. Gastrointestinal bleeding in patients receiving antiplatelet and anticoagulant therapy: practical guidance for restarting therapy and avoiding recurrences. Hellenic J Cardiol 2014;55:499-509. 6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91. 7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51. 8. Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. Gut 1996;38:316-21. 9. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000;356:1318-21. 10. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-100. 11. Anita S. Aspirin use among the adult US noninstitutionalized population, with and without indicators of heart disease, 2005. Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality, 2007. http://www.meps.ahrq.gov/mepsweb/data_files/publications/st179/stat179.pdf Accessed 11 November 2015 12. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006;7:333. 13. Higuchi T, Iwakiri R, Hara M, et al. Low-dose aspirin and comorbidities are significantly related to bleeding peptic ulcers in elderly patients compared with nonelderly patients in Japan. Intern Med 2014;53:367-73. 14. Snipelisky D, Kusumoto F. Current strategies to minimize the bleeding risk of warfarin. J Blood Med 2013;4:89. 15. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arc Intern Med 2007;167:1414-9. 16. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015;131:157-64. 17. Abraham NS, Singh S, Alexender GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;24;350:h1857. 18. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006;119:624-38.
• 19. WAVE Investigators. The effects of oral anticoagulants in patients with peripheral arterial disease: rationale, design, and baseline characteristics of the Warfarin and Antiplatelet Vascular Evaluation (WAVE) trial, including a meta-analysis of trials. Am Heart J 2006;151:1-9. 20. Abu Daya H, Eloubeidi M, Tamim H, et al. Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding. J Dig Dis 2014;15:283-92. 21. Hankey GJ, Eikelboom JW. Dabigatran etexilate a new oral thrombin inhibitor. Circulation 2011;123:1436-50. 22. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thrombosis & Haemostasis 2010;103:1116-27.